Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
CAI Stock Chart & Stats
$22.31
--
Market closed
$22.31
--
Day’s Range― - ―
52-Week Range$21.18 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.39M
Market Cap
$6.29B
Enterprise Value$5.69B
Total Cash (Recent Filing)$755.49M
Total Debt (Recent Filing)$426.74M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Feb 26, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding282,146,900
10 Day Avg. Volume2,745,115
30 Day Avg. Volume2,385,439
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)-2.85
Price to Sales (P/S)17.30
P/FCF Ratio-28.11
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue10.97
Enterprise Value/Gross Profit17.89
Enterprise Value/Ebitda-66.04
Forecast
1Y Price Target
$36.17Price Target Upside62.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.28
Revenue Forecast (FY)$999.36M
Bulls Say, Bears Say
Bulls Say
Partnerships And CommercializationAnalyst highlights a partnership with Everlywell to commercialize a blood-based multi-cancer early detection test, which could open a new commercial channel and broaden market access.
Proprietary Data And AICompany's proprietary, high-resolution dataset comprising hundreds of thousands of tumor profiles and matched clinical records supports a differentiated AI suite that could enhance diagnostic accuracy and strengthen competitive positioning.
Quarterly ResultsAnalyst notes preliminary quarterly results exceeded expectations, indicating stronger revenue momentum and operational performance that could attract investor interest.
Bears Say
Pipeline VisibilityAnalyst flags that most pipeline programs remain in early development with limited visibility into timelines, regulatory strategy, and commercialization prospects, increasing execution risk.
Product Commercialization PotentialAnalyst believes the new multi-cancer early detection test is unlikely to generate material revenue, constraining its potential to meaningfully contribute to overall company revenue.
Valuation And Analyst SentimentAnalyst maintains a hold recommendation, citing unclear valuation upside due to uncertainty around program viability and commercial impact, which may limit upside potential for the shares.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $21.18 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $6.29B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Feb 26, 2026 which is in 14 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Nov 05, 2025. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.255.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate is 0.03.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,146,900 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -15.748%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.17 (62.12% Upside)
$36.17 (62.12% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 446.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Caris Life Sciences delivered an outstanding quarter with record-breaking revenue growth, improved gross margins, and positive profitability metrics. The company achieved significant milestones including a strong balance sheet and increased ASP. However, challenges remain in pharma revenue and the dependency on revenue true-ups. The complex process for MRD approval also presents a challenge.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$36.17
▲(62.12% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---